Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative trastuzumab + durvalumab + FLOT for resectable HER2-positive gastric or gastroesophageal junction cancer
KCT0012865Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Dec 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab, durvalumab, docetaxel, oxaliplatin, fluorouracil in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Boryung. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on KCT0012865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012865.